恶性黑素瘤患者血清可溶性Fas水平变化及临床意义

Serum soluble Fas levels in malignant melanoma patients and its clinical significance

采用ELISA法检测19例恶性黑素瘤患者和21例健康人血清sFas水平，分析其与患者临床参数间的关系，探讨sFas在恶性黑素瘤中的临床意义。结果为恶性黑素瘤患者与健康人血清sFas浓度比较差异有统计学意义（中位数28．47μg／L与4．57μg／L；U=5．376，P〈0．01）。不同性别、年龄患者血清sFas浓度无差异；不同TNM分期患者和有、无远处转移患者间的sFas浓度比较差异有统计学意义（U分期=3．220，U远处转移=3．240，P〈0．01）。血清sFas水平与恶性黑素瘤的发生发展有关，并可能作为临床判断恶性黑素瘤病情的参考指标之一。

Serum soluble Fas （sFas） levels were detected by enzyme-link immunosorbent assay （ELISA） in 19 cases of malignant melanoma and 21 healthy subjects. There were statistically significant differences in serum sFas levels between malignant melanoma patients and healthy subjects （median 28. 47μg/L, 4. 67 μg/L; U = 5. 376, P 〈 0. 01 ）. No correlation was observed between serum sFas levels and gender or age of the patients. There was a significant difference in serum sFas levels either between groups with different TNM stages or between groups with and without distant metastasis （ Ustage = 3. 220, Udistant metastasis =3. 240, P 〈 0. 01 ） . Our results show that serum sFas levels were correlated with the progression of malignant melanoma, and it indicates that serum sFas may sever as an indicator for the progression of malignant melanoma.